Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Riel, J. M. G. H.
Right arrow Articles by Giaccone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Riel, J. M. G. H.
Right arrow Articles by Giaccone, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:59-63, 2004
© 2004 European Society for Medical Oncology

Original Paper

Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver

Received 14 May 2003; revised 13 August 2003; accepted 11 September 2003

Background:

Irinotecan is an active drug in colorectal cancer. In patients with liver metastases, hepatic arterial infusion of irinotecan could theoretically result in higher exposure to the drug. In order to determine the efficacy of hepatic arterial irinotecan we conducted a phase II study in pretreated patients with liver metastases of colorectal cancer.

Patients and methods:

Patients with measurable liver metastases of colorectal cancer with World Health Organization performance status (WHO PS) <2 were treated with a 5-day continuous infusion of hepatic arterial irinotecan every 3 weeks at a dose of 20 mg/m2/day.

Results:

Of the 25 patients included, 22 were evaluable for response. Three of 22 patients (13.6%) had a partial response, nine (40.9%) had stable disease and 10 (45.4%) had progressive disease. No complete responses were observed. Median time to progression was 2.8 (range 1.2–23.8) months. Major toxicities were vomiting and diarrhea. There was no major hematological toxicity.

Conclusions:

Five-day continuous hepatic arterial infusion of irinotecan 20 mg/m2/day has low activity in patients with liver metastases of colorectal cancer previously treated by chemotherapy.

J. M. G. H. van Riel1, C. J. van Groeningen2, J. de Greve3, G. Gruia4, H. M. Pinedo2 and G. Giaccone2,*

1 Department of Internal Medicine, St Elisabeth Hospital, Hilvarenbeekseweg 60, 5000 LC Tilburg, The Netherlands; 2 Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; 3 Vrije Universiteit Brussels, Belgium; 4 Aventis Pharma, Antony, France

Key words: clinical trial, colorectal cancer, intra-arterial chemotherapy, irinotecan, liver metastases, phase II study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
V. Boige, D. Malka, D. Elias, M. Castaing, T. De Baere, D. Goere, C. Dromain, M. Pocard, and M. Ducreux
Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure
Ann. Surg. Oncol., January 1, 2008; 15(1): 219 - 226.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.